Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Cash from Operations (2017 - 2025)

Sutro Biopharma's Cash from Operations history spans 9 years, with the latest figure at 38189000.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 40.81% year-over-year to 38189000.0; the TTM value through Sep 2025 reached 222534000.0, down 110.47%, while the annual FY2024 figure was 191540000.0, 71.61% down from the prior year.
  • Cash from Operations for Q3 2025 was 38189000.0 at Sutro Biopharma, up from 44724000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 65854000.0 in Q3 2022 and bottomed at 71738000.0 in Q4 2024.
  • The 5-year median for Cash from Operations is 31195000.0 (2023), against an average of 28004315.79.
  • The largest annual shift saw Cash from Operations surged 369.83% in 2022 before it crashed 879.13% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 21580000.0 in 2021, then dropped by 10.58% to 23864000.0 in 2022, then surged by 158.97% to 14072000.0 in 2023, then tumbled by 609.79% to 71738000.0 in 2024, then skyrocketed by 46.77% to 38189000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Cash from Operations are 38189000.0 (Q3 2025), 44724000.0 (Q2 2025), and 67883000.0 (Q1 2025).